Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1500-1503

  Love, Richard R ^a   Hutson, Paul R ^b   Havighurst, Thomas C ^a   Cleary, James F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AROMATASE INHIBITOR; CHOLESTEROL; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY WEIGHT DISORDER; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; OPEN STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER;

ADULT; AGED; ALKALINE PHOSPHATASE; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHOLESTEROL, HDL; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTRONE; EXANTHEMA; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 14644406843     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1610     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
2. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer: Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-7.
3. Davidson NE, O'Neill A, Vukov A, et al. Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, 1NT-0101) [abstract 15]. Proc Annu Meet Am Soc Clin Oncol 2003;22:5.
4. Roché HH, Kerbrat P, Bonneterre J, et al. Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor: results of the FASG 06 Trial [abstract 279]. Proc Annu Meet Am Soc Clin Oncol 2000;19:72a.
5. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92.
6. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
7. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
8. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
9. Zaccheo T, Giudici D, Di Salle E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol 1993;44:677-80.
10. Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Bio 2003;86:283-8.
11. Paridaens R, Therasse P, Dirix L, et al. First-line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients: a randomized phase III trial of the EORTC Breast Group [abstract 515]. Proc Annu Meet Am Soc Clin Oncol 2004;23:6.
12. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.
13. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.
14. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
15. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-11.
16. Tedeschi M, Kvinnsland S, Jones SE, et al. Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin (exemestane) in advanced breast cancer patients having progressed on antiestrogens [abstract 1270]. Eur J Cancer 1999;35:S316.
17. Yue W, Santen RJ, Wang J-P, Hamilton CJ, Demers LM. Aromatase within the breast. Endocr Relat Cancer 1999;6:157-64.
18. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999;6:235-43.
19. Rivera E, Valero V, Francis D, et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 2004;10:1943-8.
20. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
21. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
22. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997;15:974-86.
23. Johannessen DC, Engan T, DiSalle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8.
24. Woolson RF. Comparison of two groups: t-tests and rank tests. In: Statistical methods for the analysis of biomedical data. New York: John Wiley and Sons; 1987. p. 172-4.
25. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999;79:311-5.
26. Ingle JN, Suman VJ, Johnson PA, et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999;5:1642-9.
27. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338-43.
28. Goss P, Thomsen T, Banke-Bochita J, Lowery C, Asnis A. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole (abstract 267). Breast Cancer Res Treat 2002;76:S76.
29. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex and tamoxifen alone or in combination" (ATAC) trial. Br J Cancer 2001;85:317-24.
30. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-8.
31. Brodie A, Jelovac D, Long BJ. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 2003;9:455-9S.